BUDESONIDE/ FORMOTEROL INHL,ORAL
Clinical Criteria Summary
Exclusion Criteria
- Diagnosis of COPD without a concomitant diagnosis of asthma
- Inability to properly use a metered dose inhaler (MDI) (e.g., issues with dexterity)
Inclusion Criteria
- Diagnosis of Asthma
- Diagnosis of COPD with concomitant Asthma (Asthma-COPD overlap syndrome [ACOS])
Additional Inclusion Criteria & Clinical Management Guidance
- Preference for use of Maintenance and Reliever Therapy (MART) with budesonide/formoterol inhaler
- Patient is unable to tolerate or use a dry powder inhaler (DPI)
- Switching from formulary ICS/LABA (fluticasone/salmeterol) maintenance plus SABA reliever therapy to MART with budesonide/formoterol is generally not encouraged for patients whose symptoms are well controlled
- If switching to MART occurs (e.g., for step-down per GINA Track 1, steps 1-2), educate patients on using a single MDI for MART and discontinue the SABA inhaler
- If the patient prefers continued use of a SABA inhaler for symptom relief, continuation of formulary ICS/LABA is recommended instead